Wedbush Starts Audentes Therapeutics (BOLD) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks rattled, Treasuries rally after Israel attacks Iran
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Oil surges as reports of Israeli strike on Iran roil markets
- Reports of Israeli attack on Iran spark rush to Swiss franc and yen
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Cowen Starts Audentes Therapeutics (BOLD) at Outperform
August 15, 2016 6:56 AM EDTCowen initiated coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $14.70 yesterday.
... More
